Profil
Frank Gannon is the founder of Elara Pharmaceuticals GmbH, which was founded in 2006.
He held the title of Mitgründer from 2006 to 2009.
Dr. Gannon's former jobs include Executive Director at the European Molecular Biology Organization in 2007 and Senior Scientist at The European Molecular Biology Laboratory from 1994 to 2007.
Dr. Gannon received a doctorate degree from the University of Leicester in 1973.
Ehemalige bekannte Positionen von Frank Gannon
| Unternehmen | Position | Ende |
|---|---|---|
| European Molecular Biology Organization | Direktor/Vorstandsmitglied | 01.01.2007 |
| The European Molecular Biology Laboratory | Corporate Officer/Principal | 01.01.2007 |
Elara Pharmaceuticals GmbH
 Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany. | Gründer | - |
Ausbildung von Frank Gannon
| University of Leicester | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Elara Pharmaceuticals GmbH
Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany. | Health Technology |
| European Molecular Biology Organization |